Published by INCITA Clinic
On this page
AMH
Anti-Müllerian hormone is one measure used to assess ovarian reserve. It helps the doctor consider the available follicle pool in the context of the wider assessment.
A wider clinical picture
AMH is considered alongside age, antral follicle count and hormone findings. A single result should be considered together with the rest of the medical assessment.
Existing reports
Submit existing examination reports for review and ask for the current checklist. Additional or updated tests may be required.
Discussing treatment
A low AMH result does not by itself mean that IVF is impossible. Individualized assessment is needed to discuss ovarian response and the treatment options.
Quantity and quality are different questions
AMH is discussed as a marker of ovarian reserve rather than a direct test of the genetic quality of every egg. Age and other findings remain important in the treatment assessment.
Low AMH can be associated with fewer eggs available in a stimulation cycle, but the result alone does not determine whether an individual can obtain an embryo or become pregnant.
When the earlier response was low
Reviewing previous stimulation records helps the doctor understand how the ovaries responded to medication. Egg maturity, fertilization and embryo culture findings provide additional information beyond the AMH result.
The hospital describes individualized stimulation approaches and, where relevant, accumulation of eggs or embryos over more than one retrieval cycle.
Immature eggs and embryo development
Low egg number, low egg maturity and poor embryo development are different findings. IVM addresses immature eggs through an additional laboratory maturation stage, while other findings require different clinical or laboratory review.
Bring the complete record from earlier cycles so the doctor can identify which stages need attention. A single laboratory value or a brief verbal summary does not provide the whole treatment history.
Separating the questions in a consultation
Scroll across to view all columns.
| Finding | Question it helps discuss | What it does not establish alone |
|---|---|---|
| AMH | How ovarian reserve should be considered with the other findings. | The chromosome result or outcome of a particular embryo. |
| Antral follicle assessment | The ultrasound findings available for planning. | A fixed number of eggs that will be retrieved. |
| Age and reproductive history | The wider treatment and embryo-development context. | A certain result for an individual cycle. |
| Previous response | How earlier stimulation, maturity and culture stages developed. | That the same approach or result will apply again. |
When earlier treatment has already taken place
Keep the stages of each cycle separate: medication and monitoring, eggs retrieved, maturity, fertilization, blastocyst development and any genetic results. A low initial count and a later development difficulty are different questions for review.
The team can use this history to explain what needs closer assessment before another cycle. The laboratory results guide shows how the stages fit together, while age and chromosome findings explains a separate part of the discussion.
